ClinicalTrials HQ

HER2 positive breast carcinoma

HER2 positive breast carcinoma

Explore linked clinical trials. Standard reference: MONDO:0006244
View definition

13 results · Page 1 of 1

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerHER2 positive breast carcinoma, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 32026-09-29NCT05132582
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic TherapyHER2 positive breast carcinoma, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinomaRecruitingNot applicable2026-09-25NCT02945579
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialHER2 positive breast carcinoma, invasive breast carcinoma, synchronous bilateral breast carcinomaActive, not recruitingPhase 32026-06-15NCT04457596
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast CancerHER2 positive breast carcinoma, Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorderActive, not recruitingPhase 22026-03-06NCT03384914
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast CancerHER2 positive breast carcinoma, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 1 / Phase 22026-01-23NCT03368729
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast CancerHER2 positive breast carcinoma, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 22025-11-14NCT02827877
AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRIHER2 positive breast carcinomaRecruitingNot stated2025-09-24NCT06708910
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 StudyHER2 positive breast carcinoma, Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast carcinoma, breast disorder, breast neoplasm, neoplasm, skin disorderRecruitingNot stated2025-06-22NCT07030569
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical StudyHER2 positive breast carcinomaRecruitingPhase 2 / Phase 32025-05-06NCT06958627
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibHER2 positive breast carcinoma, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 22025-04-01NCT05252988
Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast CancerHER2 positive breast carcinomaActive, not recruitingNot stated2025-03-11NCT06868758
Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment CyclesHER2 positive breast carcinomaNot yet recruitingPhase 42025-03-10NCT06868017
Validation of TAD in HER-2 with More Than 2 Lymph NodesHER2 positive breast carcinomaEnrolling by invitationNot stated2025-02-12NCT06821490